eISSN: 2300-6722
ISSN: 1899-1874
Medical Studies/Studia Medyczne
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
3/2022
vol. 38
 
Share:
Share:
abstract:
Case report

The possible usefulness of a medium cut-off dialyzer in a patient with cardiomyopathy of unclear origin

Bartłomiej A. Szewczyk
1
,
Kamila Hołownia
1
,
Andrzej Jaroszyński
1, 2

1.
Medical College, Jan Kochanowski University, Kielce Poland Head of the Collegium: Prof. Marianna Janion MD, PhD
2.
Department of Nephrology, Institute of Medical Science, Jan Kochanowski University, Kielce, Poland Head of the Institute: Prof. Andrzej Jaroszyński MD, PhD
Medical Studies/Studia Medyczne 2022; 38 (3): 258–261
Online publish date: 2022/09/30
View full text Get citation
 
PlumX metrics:
The large middle molecules are a specific class of uremic toxins, which includes compounds like interleukins 1, 6, 18, tumor necrosis TNF-b, and free light chains (FLCs). Accumulation of these molecules is associated with cardiovascular complications in end-stage renal disease (ESRD). Medium cut-off (MCO) membrane provides the ability to remove large middle molecules effectively with marginal albumin leak. We present the case of 59-year-old male patient with ESRD. He was admitted to the Nephrology Clinic because of deteriorating heart failure. Moreover, the patient suffered from unclear origin cardiomyopathy. He underwent percutaneous coronary intervention. Due to worsening outcome, an attempt to use MCO treatment was made. After 6 months of MCO treatment, the patient’s clinical condition improved spectacularly. This is the first case report of the use of MCO treatment in a patient with a cardiomyopathy of unclear origin. Our study suggests that using MCO treatment in such cases may be advisable.
keywords:

medium-cut off dialyzer, cardiomyopathy, large middle molecules

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.